Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The metabolic role of growth hormone in humans with particular reference to fasting.
Nørrelund H. Nørrelund H. Growth Horm IGF Res. 2005 Apr;15(2):95-122. doi: 10.1016/j.ghir.2005.02.005. Growth Horm IGF Res. 2005. PMID: 15809014 Review. No abstract available.
Somatopause and adiposity.
Jørgensen JO, Vahl N, Fisker S, Nørrelund H, Nielsen S, Dall R, Christiansen JS. Jørgensen JO, et al. Horm Res. 1997;48 Suppl 5:101-4. doi: 10.1159/000191337. Horm Res. 1997. PMID: 9434053 Review.
Differential effects of growth hormone and prednisolone on energy metabolism and leptin levels in humans.
Wolthers T, Grøfte T, Nørrelund H, Poulsen PL, Andreasen F, Christiansen JS, Jørgensen JO. Wolthers T, et al. Metabolism. 1998 Jan;47(1):83-8. doi: 10.1016/s0026-0495(98)90197-4. Metabolism. 1998. PMID: 9440482 Clinical Trial.

GH administration decreased plasma epinephrine significantly (mean +/- SE, 34.7 +/- 5.7 ng/L for control v 24.8 +/- 5.8 for GH, P < .05), had no effect on plasma norepinephrine or serum leptin, and increased both free triiodothyronine (FT3) levels (5.7 +/- 0.3 pmol/L for contr

GH administration decreased plasma epinephrine significantly (mean +/- SE, 34.7 +/- 5.7 ng/L for control v 24.8 +/- 5.8 for GH, P < .05),

Serum leptin levels and leptin expression in growth hormone (GH)-deficient and healthy adults: influence of GH treatment, gender, and fasting.
Kristensen K, Pedersen SB, Fisker S, Nørrelund H, Rosenfalck AM, Jørgensen JO, Richelsen B. Kristensen K, et al. Metabolism. 1998 Dec;47(12):1514-9. doi: 10.1016/s0026-0495(98)90079-8. Metabolism. 1998. PMID: 9867083
Serum leptin concentrations during short-term administration of growth hormone and triiodothyronine in healthy adults: a randomised, double-blind placebo-controlled study.
Wolthers T, Lechuga A, Grøfte T, Nørrelund H, Møller N, Christiansen JS, Jørgensen JO. Wolthers T, et al. Horm Metab Res. 1999 Jan;31(1):37-40. doi: 10.1055/s-2007-978694. Horm Metab Res. 1999. PMID: 10077348 Clinical Trial.
Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels. Experimental studies in normal, obese and GH-deficient adults.
Nørrelund H, Fisker S, Vahl N, Børglum J, Richelsen B, Christiansen JS, Jørgensen JO. Nørrelund H, et al. Growth Horm IGF Res. 1999 Feb;9(1):52-60. doi: 10.1054/ghir.1998.0087. Growth Horm IGF Res. 1999. PMID: 10207508 Clinical Trial.

Conversely, a 28-h somatostatin infusion with and without GH administration during fasting in normal subjects yielded higher IGFBP-1 levels in the non-GH substituted study [50.5 +/- 5.3 (GH-suppression) vs 22.6 +/- 5.6 (GH-substitution), P < 0.01], comparable with an in

Conversely, a 28-h somatostatin infusion with and without GH administration during fasting in normal subjects yielded higher IGFBP-1 …
Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women.
Nørrelund H, Børglum J, Jørgensen JO, Richelsen B, Møller N, Nair KS, Christiansen JS. Nørrelund H, et al. Clin Endocrinol (Oxf). 2000 Mar;52(3):305-12. doi: 10.1046/j.1365-2265.2000.00937.x. Clin Endocrinol (Oxf). 2000. PMID: 10718828 Clinical Trial.
RESULTS: Protein breakdown decreased in both groups (tyrosine flux micromol/h): -12% +/- 3 (GH) vs. - 9% +/- 3 (placebo)). Phenylalanine degradation in relation to phenylalanine concentration decreased by 9% in the GH group, whereas an increase of 8% was observed in the pl …
RESULTS: Protein breakdown decreased in both groups (tyrosine flux micromol/h): -12% +/- 3 (GH) vs. - 9% +/- 3 (placebo)). Phenylalan …
Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism.
Nørrelund H, Vahl N, Juul A, Møller N, Alberti KG, Skakkebaek NE, Christiansen JS, Jørgensen JO. Nørrelund H, et al. J Clin Endocrinol Metab. 2000 May;85(5):1912-7. doi: 10.1210/jcem.85.5.6613. J Clin Endocrinol Metab. 2000. PMID: 10843174 Clinical Trial.
Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients.
Richelsen B, Pedersen SB, Kristensen K, Børglum JD, Nørrelund H, Christiansen JS, Jørgensen JO. Richelsen B, et al. Metabolism. 2000 Jul;49(7):906-11. doi: 10.1053/meta.2000.6738. Metabolism. 2000. PMID: 10910003 Clinical Trial.
Regulation of uncoupling protein (UCP) 2 and 3 in adipose and muscle tissue by fasting and growth hormone treatment in obese humans.
Pedersen SB, Borglum JD, Kristensen K, Norrelund H, Otto J, Jorgensen L, Richelsen B. Pedersen SB, et al. Int J Obes Relat Metab Disord. 2000 Aug;24(8):968-75. doi: 10.1038/sj.ijo.0801265. Int J Obes Relat Metab Disord. 2000. PMID: 10951534 Clinical Trial.
70 results
Jump to page
Feedback